Replies to post #69221 on Biotech Values

[zipjet]

Thanks DD,

>>Almost every US generic launched in the 1980s and 1990s is an example.

That is what I thought.

>>Authorized generics slide through a loophole in the Hatch-Waxman act, and it took drug companies a long time to recognize that the loophole existed.

In effect that is right. Though it seems to me that the "loophole" was the recognition that an AG was not a generic restricted/governed by Hatch-Waxman but rather a license of the patent holder.

ij